Title | Description |
|---|---|
| Trial ID | AV002 |
| Compound | Capsaicin 8% |
| Trials sponsor | Averitas Pharma, Inc |
| Trial phase | 4 |
| Brief title | Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy |
| Indication | Painful Diabetic Peripheral Neuropathy |
| UTN | |
| CTG ID | NCT06495424 |
| CTIS ID (former EudraCT) | not applicable |
| Trial status | Active, not recruiting |
| FPI | February 14, 2025 |
| LPO | |
| Countries | United States |
| Gender | All |
| Age | 18 Years to 80 Years |
| Results | No |
| Pubmed | |
| Documents |
External Link
You are now leaving the Grünenthal website. You will be re-directed to an external website. Grünenthal accepts no responsibility for the content of other websites.